Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 390-394

  Rutter, Charles E ^a   Corso, Christopher D ^a   Park, Henry S ^a   Mancini, Brandon R ^a   Yeboa, Debra N ^a   Lester Coll, Nataniel H ^a   Kim, Anthony W ^a   Decker, Roy H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Non small cell; SBRT; Stereotactic

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEMOGRAPHY; FEMALE; HEALTH CARE FACILITY; HUMAN; INOPERABLE CANCER; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PACIFIC ISLANDS; PATIENT IDENTIFICATION; PATIENT TRANSPORT; PRIORITY JOURNAL; STEREOTACTIC BODY RADIATION THERAPY; TUMOR BIOPSY; UNITED STATES; BIOPSY; CANCER STAGING; FACTUAL DATABASE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; RADIOSURGERY; RISK FACTOR; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY; DATABASES, FACTUAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOSURGERY; RISK FACTORS; TUMOR BURDEN; UNITED STATES;

EID: 84923230443     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.013     Document Type: Article

References (19)

1. Timmerman R., Paulus R., Galvin J., Michalski J., Straube W., Bradley J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303(11):1070-1076.
2. RIcardi U., Frezza G., Filippi A., Badellino S., Levis M., Navarria P., et al. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer 2014, 84(3):248-253.
3. Stanic S., Paulus R., Timmerman R., Michalski J., Barringer R., Bezjak A., et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 2014, 88(5):1092-1099.
4. Richardson C, Pointon K., Manhire A., Macfarlane J. Percutaneous lung biopsies: a survey of UK practice based on 5444 biopsies. Br J Radiol 2002, 75(897):731-735.
5. Taremi M., Hope A., Dahele M., Pearson S., Fung S., Purdie T., et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 2012, 82(2):967-973.
6. Sim Y., Goh Y., Dempsey M., Han S., Poon F. PET-CT evaluation of solitary pulmonary nodules: correlation with maximum standardized uptake value and pathology. Lung 2013, 191(6):625-632.
7. Colbert L., Hall W., D.Nickleach, Switchenko J., Kooby D., Liu Y., et al. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 2014, 120(4):499-506.
8. Corso C.D., Moreno A.C., Kim A.W., Husain Z., Yu J.B., Decker R.H. Stage I Lung SBRT Clinical Practice Patterns. 96th Annual Meeting of the American Radium Society 2014.
9. Lagerwaard F., Haasbeek C., Smith E., Slotman B., Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70(3):685-692.
10. Cykert S., Dilworth-Anderson P., Monroe M., Walker P., McGuire F., Corbie-Smith G. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 2010, 303(23):2368-2376.
11. Fish G., Stanley J., Miller K., Schabel S., Sutherland S. Postbiopsy pneumothorax: estimating the risk by chest radiography and pulmonary function tests. AJR Am J Roentgenol 1988, 150(1):71-74.
12. Southern D.A., Quan H., Ghali W.A. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 2004, 42(4):355-360.
13. Roberts K., Soulos P., Herrin J., Yu J., Long J., Dostaler E. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications. Int J Radiat Oncol Biol Phys 2013, 85(5):1186-1192.
14. Guadagnolo B., Huo J., Liao K., Buckholz T., Das P. Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States. Cancer 2013, 119(5):1089-1097.
15. Swensen S., Silverstein M., Ilstrup D., Schleck C., Edell E. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997, 157(8):849-855.
16. Gould M., Anath L., Barnett P. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 2007, 131(2):383-388.
17. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24(30):4833-4839.
18. Duhaylongsod F., Lowe V., Patz E., Vaughn A.., Coleman R., Wolfe W., et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995, 110(1):130-139. discussion 139-40.
19. Siegelman S., Zerhouni E., Leo F., Khouri N., Stitik F. CT of the solitary pulmonary nodule. AJR Am J Roentgenol 1980, 135(1):1-13.